Annovis Bio, Inc.
ANVS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ANVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANVS
Annovis Bio, Inc. is a late-stage clinical company developing buntanetap for neurodegenerative diseases such as Alzheimer's and Parkinson's, with a focus on addressing unmet needs in aging populations.
Key risk: Insufficient capital runway
BioSniper Score
Based on 6 of 6 signals
Market Cap
$73.3M
Cash Runway
2.6 moLead Asset
ANVS405 (Preclinical)
Next Catalyst
Phase3_Topline · Jun 1, 2028Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 3 catalysts for Annovis Bio, Inc..
Annovis Bio, Inc. is a late-stage clinical company developing buntanetap for neurodegenerative diseases such as Alzheimer's and Parkinson's, with a focus on addressing unmet needs in aging populations.
- Annovis Bio is a late-stage clinical company addressing neurodegeneration, such as Alzheimer's disease [sec_mda · as of 2026-08-14].
- The company's lead product candidate is buntanetap, targeting two large U.S. markets if approved [sec_mda · as of 2026-05-15].
- As of 2026-06-30, the company reported cash and equivalents of $18.7 million, zero revenue, and a net loss of $14.8 million [sec].
- The accumulated deficit was $181.3 million as of March 31, 2026 [sec_mda · as of 2026-05-15].
- The company has never been profitable and expects losses to increase as it ramps up clinical development and commercial launch readiness [sec_mda · as of 2026-08-14].
What works
- Annovis Bio is a late-stage clinical company with a product candidate, buntanetap, targeting two large U.S. markets in Alzheimer's and Parkinson's disease [sec_mda · as of 2026-05-15].
- The company has ongoing clinical trials, including a Phase 3 topline readout expected in 2028, indicating progress in its development pipeline [catalyst_timeline].
- The company has raised capital through equity offerings, such as $6.8 million in gross proceeds from stock sales in 2025 [sec_mda · as of 2026-03-13].
What to weigh
- Annovis Bio has never been profitable and has incurred net losses since inception, with an accumulated deficit of $181.3 million as of March 31, 2026 [sec_mda · as of 2026-05-15].
- The company does not have sufficient capital to fund operations for the next 12 months and will need to raise additional capital to meet obligations [sec_mda · as of 2026-05-15].
- Cash and equivalents of $18.7 million as of 2026-06-30 may only fund operations until the fourth quarter of 2026, based on prior guidance [sec_mda · as of 2026-05-15].
- The company faces risks from unforeseen expenses, difficulties, and delays in clinical trials, which could adversely affect its business [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
The company is a late-stage clinical company addressing neurodegeneration.
“We are a late-stage clinical company addressing neurodegeneration, such as Alzheimer's”
SEC MD&A · August 14, 2026
The company has never been profitable and has a significant accumulated deficit.
“We have never been profitable and have incurred net losses since inception. Our accumulated deficit at March 31, 2026 was $181.3 million.”
SEC MD&A · May 15, 2026
The company expects losses to increase as it ramps up clinical development.
“also expect these losses to further increase, as we ramp up our clinical development programs and begin activities for commercial launch readiness.”
SEC MD&A · August 14, 2026
The company does not have sufficient capital for the next 12 months.
“We do not have sufficient capital on hand to fund our operations for the next 12 months and will need to raise additional capital to meet our obligations as they become due.”
SEC MD&A · May 15, 2026
Catalyst timeline
- 2028-06-01 · Phase3_Topline — Phase 3 Topline: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial I — This topline readout will provide efficacy and safety data for buntanetap in a dual trial setting.
- 2029-11-01 · Phase3_Topline — Phase 3 Topline: An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participan — This open-label trial will assess long-term safety of buntanetap in participants.
- 2030-05-01 · Phase3_Topline — Phase 3 Topline: An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participan — This additional open-label trial will further evaluate long-term safety of buntanetap.
Risks & what to watch (4)›
Key risks
- Insufficient capital runway — Cash may only fund operations until Q4 2026; additional capital needed [sec_mda · as of 2026-05-15].
- Clinical trial uncertainties — Unforeseen expenses, delays, or difficulties in trials could harm business [sec_mda · as of 2026-08-14].
- No approved products or revenue — Company has zero revenue and relies on future product approval [sec].
- Regulatory and commercial risks — Ability to obtain and maintain regulatory approval is uncertain [sec_mda · as of 2026-08-14].
What to watch
- Phase 3 topline data for buntanetap expected in June 2028 [catalyst_timeline].
- Ability to raise additional capital to extend cash runway beyond Q4 2026 [sec_mda · as of 2026-05-15].
- Progress in patient enrollment and clinical trial execution for buntanetap [sec_mda · as of 2026-08-14].
- Regulatory submissions and updates on approval pathways [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Annovis Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Annovis Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
2.6 months
OCF -$22M · Net income -$15M
Lead: Phase 3
2 candidates
3 upcoming, next in ~641d
4 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
57
Total value held
$13.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,744,762 | $3.9M |
| marshall wace, llp | 1,187,499 | $2.6M |
| two sigma investments, lp | 627,659 | $1.4M |
| susquehanna international group, llp | 541,036 | $1.2M |
| renaissance technologies llc | 347,600 | $775K |
| geode capital management, llc | 247,513 | $552K |
| northern trust corp | 141,730 | $316K |
| blackrock, inc. | 139,533 | $311K |
| vanguard fiduciary trust co | 132,042 | $294K |
| citadel advisors llc | 104,900 | $234K |
Showing top 10 of 57 institutional holders of Annovis Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 15.6%
- Days to cover
- 3.7
- Shares short
- 4,816,770
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANVS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Annovis Bio, Inc.?
Annovis Bio, Inc. is a late-stage clinical company developing buntanetap for neurodegenerative diseases such as Alzheimer's and Parkinson's, with a focus on addressing unmet needs in aging populations.
What is Annovis Bio, Inc.'s lead drug candidate?
Annovis Bio, Inc.'s most advanced tracked candidate is ANVS405 (Preclinical) for Traumatic brain injury and stroke.
What is Annovis Bio, Inc.'s next catalyst?
Annovis Bio, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial I" — expected June 1, 2028.
Who is the CEO of Annovis Bio, Inc.?
Dr. Maria L. Maccecchini Ph.D. is the chief executive officer of Annovis Bio, Inc. (ANVS).
Where is Annovis Bio, Inc. headquartered?
Annovis Bio, Inc. (ANVS) is headquartered in Malvern, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.